Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy

A retrospective multicenter analysis (KROG 1418)

Yeon Joo Kim, Won Park, Boram Ha, Boram Park, Jungnam Joo, Tae Hyun Kim, In Hae Park, Keun Seok Lee, Eun Sook Lee, Kyung Hwan Shin, Haeyoung Kim, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yongbae Kim, Sung Ja Ahn, Jong Hoon Lee & 5 others Jin Hee Kim, Mison Chun, Hyung Sik Lee, Jung Soo Kim, Jihye Cha

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [-]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.

Original languageEnglish
Pages (from-to)927-936
Number of pages10
JournalCancer Research and Treatment
Volume49
Issue number4
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Radiotherapy
Breast Neoplasms
Drug Therapy
Disease-Free Survival
Recurrence
Survival
Modified Radical Mastectomy
taxane
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Yeon Joo ; Park, Won ; Ha, Boram ; Park, Boram ; Joo, Jungnam ; Kim, Tae Hyun ; Park, In Hae ; Lee, Keun Seok ; Lee, Eun Sook ; Shin, Kyung Hwan ; Kim, Haeyoung ; Yu, Jeong Il ; Choi, Doo Ho ; Huh, Seung Jae ; Wee, Chan Woo ; Kim, Kyubo ; Park, Kyung Ran ; Kim, Yongbae ; Ahn, Sung Ja ; Lee, Jong Hoon ; Kim, Jin Hee ; Chun, Mison ; Lee, Hyung Sik ; Kim, Jung Soo ; Cha, Jihye. / Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy : A retrospective multicenter analysis (KROG 1418). In: Cancer Research and Treatment. 2017 ; Vol. 49, No. 4. pp. 927-936.
@article{a6e5be0d2a5d4ff5ac7cb2ba22d486c7,
title = "Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)",
abstract = "Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97{\%}, 94{\%}, and 98{\%}, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96{\%}, 90{\%}, and 96{\%}, respectively, in patients who did not receive PMRT (PMRT [-]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.",
author = "Kim, {Yeon Joo} and Won Park and Boram Ha and Boram Park and Jungnam Joo and Kim, {Tae Hyun} and Park, {In Hae} and Lee, {Keun Seok} and Lee, {Eun Sook} and Shin, {Kyung Hwan} and Haeyoung Kim and Yu, {Jeong Il} and Choi, {Doo Ho} and Huh, {Seung Jae} and Wee, {Chan Woo} and Kyubo Kim and Park, {Kyung Ran} and Yongbae Kim and Ahn, {Sung Ja} and Lee, {Jong Hoon} and Kim, {Jin Hee} and Mison Chun and Lee, {Hyung Sik} and Kim, {Jung Soo} and Jihye Cha",
year = "2017",
month = "1",
day = "1",
doi = "10.4143/crt.2016.508",
language = "English",
volume = "49",
pages = "927--936",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "4",

}

Kim, YJ, Park, W, Ha, B, Park, B, Joo, J, Kim, TH, Park, IH, Lee, KS, Lee, ES, Shin, KH, Kim, H, Yu, JI, Choi, DH, Huh, SJ, Wee, CW, Kim, K, Park, KR, Kim, Y, Ahn, SJ, Lee, JH, Kim, JH, Chun, M, Lee, HS, Kim, JS & Cha, J 2017, 'Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)', Cancer Research and Treatment, vol. 49, no. 4, pp. 927-936. https://doi.org/10.4143/crt.2016.508

Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy : A retrospective multicenter analysis (KROG 1418). / Kim, Yeon Joo; Park, Won; Ha, Boram; Park, Boram; Joo, Jungnam; Kim, Tae Hyun; Park, In Hae; Lee, Keun Seok; Lee, Eun Sook; Shin, Kyung Hwan; Kim, Haeyoung; Yu, Jeong Il; Choi, Doo Ho; Huh, Seung Jae; Wee, Chan Woo; Kim, Kyubo; Park, Kyung Ran; Kim, Yongbae; Ahn, Sung Ja; Lee, Jong Hoon; Kim, Jin Hee; Chun, Mison; Lee, Hyung Sik; Kim, Jung Soo; Cha, Jihye.

In: Cancer Research and Treatment, Vol. 49, No. 4, 01.01.2017, p. 927-936.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy

T2 - A retrospective multicenter analysis (KROG 1418)

AU - Kim, Yeon Joo

AU - Park, Won

AU - Ha, Boram

AU - Park, Boram

AU - Joo, Jungnam

AU - Kim, Tae Hyun

AU - Park, In Hae

AU - Lee, Keun Seok

AU - Lee, Eun Sook

AU - Shin, Kyung Hwan

AU - Kim, Haeyoung

AU - Yu, Jeong Il

AU - Choi, Doo Ho

AU - Huh, Seung Jae

AU - Wee, Chan Woo

AU - Kim, Kyubo

AU - Park, Kyung Ran

AU - Kim, Yongbae

AU - Ahn, Sung Ja

AU - Lee, Jong Hoon

AU - Kim, Jin Hee

AU - Chun, Mison

AU - Lee, Hyung Sik

AU - Kim, Jung Soo

AU - Cha, Jihye

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [-]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.

AB - Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [-]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.

UR - http://www.scopus.com/inward/record.url?scp=85030762872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030762872&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.508

DO - 10.4143/crt.2016.508

M3 - Article

VL - 49

SP - 927

EP - 936

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 4

ER -